Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy
Eugene D. Kwon(National Institutes of Health), Maurice B. Burg(National Heart Lung and Blood Institute), Barbara A. Foster(Roswell Park Comprehensive Cancer Center), Norman M. Greenberg(Baylor College of Medicine), Arthur A. Hurwitz(SUNY Upstate Medical University), Chris Madias(National Institutes of Health), James P. Allison(The University of Texas MD Anderson Cancer Center)
Cited by 223
Related Papers
Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
|New England Journal of Medicine|2012|2.1k
The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research
|Clinical Cancer Research|2009|1.4k
Cancer classification using the Immunoscore: a worldwide task force
|Journal of Translational Medicine|2012|803
Cellular Response to Hyperosmotic Stresses
|Physiological Reviews|2007|790
The Next Decade of Immune Checkpoint Therapy
|Cancer Discovery|2021|739